Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 30 May 2024, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Marksans Pharma declined 4.44% to Rs 78.29 crore in the quarter ended March 2024 as against Rs 81.93 crore during the previous quarter ended March 2023. Sales rose 15.23% to Rs 560.01 crore in the quarter ended March 2024 as against Rs 485.98 crore during the previous quarter ended March 2023.For the full year,net profit rose 17.80% to Rs 313.70 crore in the year ended March 2024 as against Rs 266.31 crore during the previous year ended March 2023. Sales rose 17.56% to Rs 2177.41 crore in the year ended March 2024 as against Rs 1852.14 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales560.01485.98 15 2177.411852.14 18 OPM %19.5822.54 -21.0618.32 - PBDT121.33118.12 3 497.80389.51 28 PBT100.28104.17 -4 423.53337.65 25 NP78.2981.93 -4 313.70266.31 18 Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary, Relonchem has received marketing authorization for the product Levetiracetam Relonchem 100 mg/mL oral solution from UK MHRA. The product will be manufactured at the Group`s UK manufacturing facility. Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2024Powered by Capital Market - Live News

Marksans Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9 April 2024 to 17 April 2024.On conclusion of the inspection, the Company has received 5 inspectional observations in form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.Powered by Capital Market - Live News